tetano
Editor, Senior Moderator
Virol J
. 2024 Apr 26;21(1):96.
doi: 10.1186/s12985-024-02367-1. Presepsin as a prognostic biomarker in COVID-19 patients: combining clinical scoring systems and laboratory inflammatory markers for outcome prediction
Zhipeng Wu[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Nan Geng[SUP] #[/SUP][SUP] 4 [/SUP], Zhao Liu[SUP] 4 [/SUP], Wen Pan[SUP] 4 [/SUP], Yueke Zhu[SUP] 4 [/SUP], Jing Shan[SUP] 4 [/SUP], Hongbo Shi[SUP] 2 [/SUP], Ying Han[SUP] 5 [/SUP], Yingmin Ma[SUP] 6 7 8 [/SUP], Bo Liu[SUP] 9 [/SUP]
Affiliations
Background: There is still limited research on the prognostic value of Presepsin as a biomarker for predicting the outcome of COVID-19 patients. Additionally, research on the combined predictive value of Presepsin with clinical scoring systems and inflammation markers for disease prognosis is lacking.
Methods: A total of 226 COVID-19 patients admitted to Beijing Youan Hospital's emergency department from May to November 2022 were screened. Demographic information, laboratory measurements, and blood samples for Presepsin levels were collected upon admission. The predictive value of Presepsin, clinical scoring systems, and inflammation markers for 28-day mortality was analyzed.
Results: A total of 190 patients were analyzed, 83 (43.7%) were mild, 61 (32.1%) were moderate, and 46 (24.2%) were severe/critically ill. 23 (12.1%) patients died within 28 days. The Presepsin levels in severe/critical patients were significantly higher compared to moderate and mild patients (p < 0.001). Presepsin showed significant predictive value for 28-day mortality in COVID-19 patients, with an area under the ROC curve of 0.828 (95% CI: 0.737-0.920). Clinical scoring systems and inflammation markers also played a significant role in predicting 28-day outcomes. After Cox regression adjustment, Presepsin, qSOFA, NEWS2, PSI, CURB-65, CRP, NLR, CAR, and LCR were identified as independent predictors of 28-day mortality in COVID-19 patients (all p-values < 0.05). Combining Presepsin with clinical scoring systems and inflammation markers further enhanced the predictive value for patient prognosis.
Conclusion: Presepsin is a favorable indicator for the prognosis of COVID-19 patients, and its combination with clinical scoring systems and inflammation markers improved prognostic assessment.
Keywords: 28-day mortality; COVID-19; Clinical scoring systems; Inflammation-related markers; Presepsin; Soluble CD14.
. 2024 Apr 26;21(1):96.
doi: 10.1186/s12985-024-02367-1. Presepsin as a prognostic biomarker in COVID-19 patients: combining clinical scoring systems and laboratory inflammatory markers for outcome prediction
Zhipeng Wu[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Nan Geng[SUP] #[/SUP][SUP] 4 [/SUP], Zhao Liu[SUP] 4 [/SUP], Wen Pan[SUP] 4 [/SUP], Yueke Zhu[SUP] 4 [/SUP], Jing Shan[SUP] 4 [/SUP], Hongbo Shi[SUP] 2 [/SUP], Ying Han[SUP] 5 [/SUP], Yingmin Ma[SUP] 6 7 8 [/SUP], Bo Liu[SUP] 9 [/SUP]
Affiliations
- PMID: 38671532
- PMCID: PMC11046891
- DOI: 10.1186/s12985-024-02367-1
Background: There is still limited research on the prognostic value of Presepsin as a biomarker for predicting the outcome of COVID-19 patients. Additionally, research on the combined predictive value of Presepsin with clinical scoring systems and inflammation markers for disease prognosis is lacking.
Methods: A total of 226 COVID-19 patients admitted to Beijing Youan Hospital's emergency department from May to November 2022 were screened. Demographic information, laboratory measurements, and blood samples for Presepsin levels were collected upon admission. The predictive value of Presepsin, clinical scoring systems, and inflammation markers for 28-day mortality was analyzed.
Results: A total of 190 patients were analyzed, 83 (43.7%) were mild, 61 (32.1%) were moderate, and 46 (24.2%) were severe/critically ill. 23 (12.1%) patients died within 28 days. The Presepsin levels in severe/critical patients were significantly higher compared to moderate and mild patients (p < 0.001). Presepsin showed significant predictive value for 28-day mortality in COVID-19 patients, with an area under the ROC curve of 0.828 (95% CI: 0.737-0.920). Clinical scoring systems and inflammation markers also played a significant role in predicting 28-day outcomes. After Cox regression adjustment, Presepsin, qSOFA, NEWS2, PSI, CURB-65, CRP, NLR, CAR, and LCR were identified as independent predictors of 28-day mortality in COVID-19 patients (all p-values < 0.05). Combining Presepsin with clinical scoring systems and inflammation markers further enhanced the predictive value for patient prognosis.
Conclusion: Presepsin is a favorable indicator for the prognosis of COVID-19 patients, and its combination with clinical scoring systems and inflammation markers improved prognostic assessment.
Keywords: 28-day mortality; COVID-19; Clinical scoring systems; Inflammation-related markers; Presepsin; Soluble CD14.